Portal de investigação
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Magalhaes, D
- Patita, M
- Arroja, B
- Lago, P
- Rosa, I
- de Sousa, HT
- Ministro, P
- Mocanu, I
- Vieira, A
- Castela, J
- Moleiro, J
- Roseira, J
- Cancela, E
- Sousa, P
- Portela, F
- Correia, L
- Santiago, M
- Dias, S
- Alves, C
- Afonso, J
- Danese, S
- Peyrin-Biroulet, L
- GEDII
Unidades de investigação
Abstract
BACKGROUND AND AIMS: Subclinical intestinal inflammation is common in Crohn's disease (CD). We aimed to explore its impact in the disease progression of infliximab-treated patients and the usefulness of fecal calprotectin (FC) and C-reactive protein (CRP) as surrogate minimally invasive biomarkers. METHODS: The registry-based, prospective, observational, multicenter DIRECT (study to investigate the correlation of fecal calprotectin with serum Drug levels and development of an antI-dRug antibodiEs among adult patients with inflammatory bowel disease reCeiving anti-TNF-alfa treatment or vedoluzimab treatment) study followed infliximab-treated CD patients for 2 years in a tertiary care setting. Persistent inflammation definition was based on FC (>150 mu g/g, >250 mu g/ g, or >350 mu g/g) or serum CRP (>3 mu g/mL) concentrations over 2 consecutive or at least 3 visits. Patients were categorized according to a composite outcome reflecting disease progression that incorporated surgery; hospitalizations; new fistulae, abscess, or stricture; and treatment escalation. RESULTS: Of 322 DIRECT study patients, 180 asymptomatic, infliximab treated on maintenance regimen were included in the analysis. Patients developing the composite endpoint (n = 96) presented higher median levels of FC (205 [interquartile range, 98-515] mu g/g; P = .045) but not of CRP (2.50 [interquartile range, 0.80-6.00] mu g/mL; P = .895). Biomarker-defined persistent subclinical inflammation prevalence ranged from 24% to 81%. Considering FC >250 mu g/g in 2 consecutive visits, prevalence was 50%, odds of achieving the endpoint were increased 3-fold (odds ratio, 2.996 [95% confidence interval, 1.557-5.776]), and time-to-outcome occurrence was significantly lower among subjects with persistent inflammation (median time: 11 months). Both clinical-related and treatment-related components were significantly associated with persistent inflammation. Definitions based on CRP >3 mu g/mL, FC >150 mu g/g, FC >350 mu g/g, double biomarkers (FC >250 mu g/g and/or CRP >3 mu g/mL), or more visits did not improve predictive ability. CONCLUSIONS: Persistent inflammation, defined simply and readily by FC >250 mu g/g over 2 consecutive visits, was associated with a significantly higher risk and shorter time to occurrence of a composite outcome reflecting disease progression in asymptomatic infliximab-treated CD patients.
Dados da publicação
- ISSN/ISSNe:
- 1542-7714, 1542-3565
- Tipo:
- Article
- Páginas:
- 2059-20737
- Link para outro recurso:
- www.scopus.com
Clinical Gastroenterology and Hepatology W.B. Saunders Ltd
Citações Recebidas na Web of Science: 4
Citações Recebidas na Scopus: 9
Documentos
- Não há documentos
Filiações
Keywords
- Inflammatory Bowel Disease; Anti-TNF-alpha; C-Reactive Protein; Fecal Calprotectin
Financiamento
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Isolated Ulceration of Crohn’s Anastomosis
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
Magro F,Magalhaes D,Patita M,Arroja B,Lago P,Rosa I,de Sousa HT,Ministro P,Mocanu I,Vieira A,Castela J,Moleiro J,Roseira J,Cancela E,Sousa P,Portela F,Correia L,Santiago M,Dias S,Alves C,Afonso J,Danese S,Peyrin L,Dias CC,G. Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years. Clin. Gastroenterol. Hepatol. 2022. 20. (9):p. 2059-20737. IF:12,600. (1).
